Trials / Completed
CompletedNCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or R/R diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Advanced Solid Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-10188 | Administered as specified in the treatment arm |
| DRUG | Zanubrutinib | Administered as specified in the treatment arm |
| DRUG | Tislelizumab | Administered as specified in the treatment arm |
Timeline
- Start date
- 2020-04-29
- Primary completion
- 2024-08-28
- Completion
- 2024-08-28
- First posted
- 2020-02-24
- Last updated
- 2026-02-20
- Results posted
- 2026-02-20
Locations
24 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT04282018. Inclusion in this directory is not an endorsement.